Clinical Study

Assessment of T Regulatory Cells and Expanded Profiling of Autoantibodies May Offer Novel Biomarkers for the Clinical Management of Systemic Sclerosis and Undifferentiated Connective Tissue Disease

Table 3

Frequency of reactivity to nuclear, nucleolar, or cytoplasmic antigens.

Antibody reactivity Diagnosis
lcSSc (14) dcSSc (11) UCTD (23)

P/NP/NP/N

ANA (I.F.A.) 14/011/018/5 0.02
Cenp-A/B 11/33/8 0/23 <0.0001
Scl-70 0/14 6/50/23 <0.0001
Ro-52 2/12 3/8 1/22
RNP 0/14 0/11 7/160.011
Mi-2 1/13 1/10 0/23
PM/Scl 1/13 1/10 5/18
NOR 2/12 1/10 2/21
Ku 1/13 2/9 3/20
RP 1/13 0/11 1/22
PL-7-12 0/14 3/80/23 0.005
SRP 0/14 4/71/22 0.005
Jo-1 0/14 0/11 0/23
≥2 antigens 4/7 8/63/20 0.017